New agents for the treatment of cancer-related fatigue.
Burks
T F
TF
Department of Integrative Biology and Pharmacology, The University of Texas-Houston Medical School, Texas 77225, USA.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001920:Bradykinin / Q000037:antagonists & inhibitors; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D005221:Fatigue / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D008565:Membrane Proteins; D009369:Neoplasms / Q000150:complications*; D010431:Pentoxifylline / Q000627:therapeutic use; D011451:Prostaglandin-Endoperoxide Synthases; D000521:alpha-MSH / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007527:Isoenzymes; D008565:Membrane Proteins; D000521:alpha-MSH; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; C496511:PTGS1 protein, human; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D001920:Bradykinin; D010431:Pentoxifylline